Kornimate/medical-research-clean huggingface dataset:
variations in retinal nerve fiber layer thickness during uncomplicated anterior and intermediate uveitis

Conditions: Anterior Uveitis; Intermediate Uveitis

Summary: this study investigates the variations in the retinal nerve fiber layer (rnfl) thickness during uncomplicated anterior and intermediate uveitis, respectively. the objectives are to 1 ) confirm the rnfl thickening during an uncomplicated anterior uveitis as described in the literature, 2) measure the rnfl thickness during an uncomplicated intermediate uveitis specifically and 3) describe the variation in time of rnfl thickness during the two types of uveitis.

thirty six individuals (18 with anterior uveitis and 18 with intermediate uveitis) will be recruited at the centre universitaire d'ophtalmologie du chu de québec. rnfl thickness will be measured with optical coherence tomography at 3 times. for anterior uveitis, the rnfl thickness will be measured at presentation, 1 week and 4 to 6 weeks. for intermediate uveitis, the rnfl thickness will be measured at presentation, 4 to 6 weeks and 4 months. the initial thickness will be studied for each type of uveitis and progression over time will be studied also for each type of uveitis.

Eligibility criteria:
inclusion criteria: * 18 years old or more * anterior uncomplicated uveitis or intermediate uncomplicated uveitis exclusion criteria: * history of uveitis in the past, other than the actual uveitis * history of ophthalmologic pathology with potential impact on retinal nerve fiber layer thickness * optic nerve or macular clinically apparent edema * history of glaucoma or other optic neuropathy * suspected or confirmed multiple sclerosis * ocular hypertension (intraocular pressure more than 22 mmhg) * reduced optical coherence tomography signal (lower than 7) on the cirrus hd-oct
patent foramen ovale closure reduce in scuba-divers

Conditions: Patent Foramen Ovale; Decompression Illness

Summary: it has been proposed that there would not be an increased risk of dci after closure of the interatrial communication, i.e. patent foramen ovale (pfo).


Eligibility criteria:
inclusion criteria: * catheter-based pfo-closure because of dci exclusion criteria: -
supplementing intracytoplasmic sperm injection handling medium with chaetoglobosin a ( icsi-ca)

Conditions: Infertility

Summary: vienna consensus has identified 10% damage rate after icsi as a competency value. despite the highest quality embryologists doing icsi, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. chaetoglobosin a serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. using chaetoglobosin a during icsi could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes.


Eligibility criteria:
inclusion criteria: * all icsi participants agreed exclusion criteria: -
to evaluate the efficacy and safety of peg-rhg-csf（jinyouli®） in reducing neutropenia in patients with cervical cancer

Conditions: Cervical Cancer

Summary: a prospective, open, randomized, controlled clinical study to evaluate the efficacy and safety of peg-rhg-csf(pegylated recombinant human granulocyte stimulating factor injection) in reducing neutropenia during tp(docetaxel+cisplatin) regiment simultaneous radiochemotherapy and adjuvant chemotherapy in patients with cervical cancer


Eligibility criteria:
inclusion criteria: 1. age ≥18, ≤70 years old; 2. cervical cancer patients diagnosed by histopathology; 3. need to receive multi-cycle radical concurrent radiochemotherapy; 4. fn risk \> 20% if rhg-csf was not accepted; high risk factors associated with fn and planed to use the same protocol in subsequent cycles(docetaxel+cisplatin regimen)； 5. performance status score(kps)≥70; 6. no obvious blood system disease,absolute neutrophil count（anc）≥ 1.5×10\^9/l, platelet count≥80×10\^9 /l, hemoglobin（hb）≥75 g/l, and no bleeding tendency; 7. the patient signs the informed consent. exclusion criteria: 1. with infection difficult to control, or received system antibiotic treatment within 72 h before chemotherapy; 2. any bone marrow abnormalities and other hematopoietic ; 3. had received bone marrow or hematopoietic stem cell transplantation within 3 months; 4. with other malignancies not cure, or with brain metastases; 5. liver function tests:total bilirubin(tbil), alanine aminotransferase (alt) and aspartate aminotransferase (ast) were all ≥2.5 times normal upper limit. 6. renal function tests: serum creatinine (cr)\> 1.5 times normal upper limit; 7. allergic to the drugs or other genetic engineering biological products from escherichia coli; 8. suffering from mental or neurological disorders; 9. investigator think it is not suitable for recruiting.
identification of viral variants involved in the transmission of hepatitis c and characterization of antigenic and functional properties of their envelope glycoproteins

Conditions: Hepatitis C

Summary: the study consists to identify viral variants involved in the transmission of hepatitis c and characterize the antigenic and functional properties of their envelope glycoproteins at very early stage of infection (before seroconversion).


Eligibility criteria:
inclusion criteria: * age \> 18 years * agree to participate in this study (signing the consent form or information form signed and letter of no objection for subjects contaminated by blood exposure). these criteria are specific to contaminated subjects: * primary infection before development of hcv antibody (seroconversion): nucleic acid testing positive in the absence of hcv antibodies. these criteria are specific to individual sources : * hcv antibody positive. exclusion criteria: * refusal to participate * private about freedom * under guardianship * under justice * minor or major person unable to consent
safety and effectiveness evaluation of the sinusway device for endoscopy of the nasal cavity and paranasal sinuses

Conditions: Sinusitis

Summary: 3nt flexible endoscope is a single-use disposable handheld endoscope that provides a means to visualize the nasal cavity and paranasal sinus space and deliver irrigation to treat the sinus ostia and spaces within the paranasal sinus cavities for diagnostic and therapeutic procedures.

the rationale behind this feasibility study is to show that accessing and visualization of the nasal anatomy and paranasal sinuses (maxillary, frontal and sphenoid sinuses) in patients suffering from symptoms attributable to sinusitis is feasible; this is an essential step in the development of a system that will later allow visualization, sampling, and treatment of the sinuses via the natural sinus ostium during the patient's first office visit in a minimally invasive manner while enabling treatment by lavage, and minimizing radiation exposure, antibiotic use, multiple office visits, and cost.

Eligibility criteria:
inclusion criteria: * male or female patient indicated for primary fess procedure by the ear, nose and throat (ent) specialist * patient age: adult (\>18 years old) * patients in general good health in the opinion of the investigator as determined by medical history physical examination * a patient who is able to understand the requirements of the study, is willing to comply with its instructions and schedules, and agrees to sign the informed consent exclusion criteria: * a patient with nasal polyposis * a patient indicated for tumor excision * known history of any significant medical disorder, which in the investigator's judgment contraindicates the patient's participation * patients with known current or previous bleeding disorder receiving anticoagulants (e.g., chronic coumadin treatment) * pregnancy * patients with previous fess surgery
open-label safety, pk, and efficacy trial of sebetralstat (kvd900) in pediatric patients (ages 2-11) with hae type i or ii

Conditions: Hereditary Angioedema

Summary: kvd900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with hae type i or ii.


Eligibility criteria:
inclusion criteria: 1. male or female patients 2 to 11 years of age. 2. confirmed diagnosis of hae type i or ii. 3. for patients ≥20 kg at screening, patient has had at least 1 documented hae attack in the last year prior to screening. 4. caregiver, as assessed by the investigator, must be able to appropriately store and administer imp and be able to read, understand, and complete the diary. 5. investigator believes that the patient and caregiver are willing and able to adhere to all protocol requirements. 6. parent or legally authorized representative (lar) provides signed informed consent and patient provides assent (when applicable). exclusion criteria: 1. any concomitant diagnosis of another form of chronic angioedema, such as acquired c1 inhibitor deficiency, hae with normal c1-inh, idiopathic angioedema, or angioedema associated with urticaria. 2. a clinically significant history of poor response to bradykinin receptor 2 blocker, c1-inh therapy, or plasma kallikrein inhibitor therapy for the management of hae, in the opinion of the investigator. 3. patient weighs \<9.5 kg. 4. use of angiotensin-converting enzyme inhibitors after the screening visit. 5. any estrogen-containing medications with systemic absorption (such as oral contraceptives including ethinylestradiol or hormonal replacement therapy) within 7 days prior to the screening visit. 6. patients who require sustained use of strong cytochrome p450 3a4 (cyp3a4) inhibitors or inducers or moderate cyp3a4 inducers. 7. any clinically significant comorbidity or systemic dysfunction, which in the opinion of the investigator, would jeopardize the safety of the patient by participating in the trial. 8. known hypersensitivity to sebetralstat or to any of the excipients. 9. participation in any interventional investigational clinical trial within 4 weeks of the last dosing of investigational drug prior to the screening visit.

Keywords: konfident-kid
aging brain changes, executive dysfunction and depression

Conditions: Depression

Summary: the purpose of this study is to look at the relationship between age related structural brain changes and changes in depressive symptoms,disability and several aspects of cognitive functioning following treatment with escitalopram.

age-related brain changes have been associated with development of late-life depression. prominent among aging-related changes is decline in white matter disproportionately affecting frontal structures.based on previous findings, we conceptualized treatment resistance, disability, and executive dysfunction as clinical phenomena contributed, at least in part, by compromised integrity of frontal neural systems. the study focuses on frontal white matter abnormalities in geriatric depression and their relationship to treatment response, disability,and executive dysfunction.

Eligibility criteria:
inclusion criteria: 1. age: two strata: 60-74 years (n=60) subjects and 75-84 years (n=60). 2. diagnosis: major depression, unipolar (by dsm-iv criteria); or, for control subjects, no diagnosis of major depression, no history of depression or other psychiatric conditions. 3. severity of depression: a 24-item hdrs above 19; level of executive dysfunction: two strata within each age stratum: stroop color-word scores below and above 24 (1 sd below the median of our normal elderly sample). exclusion criteria: 1. psychotic depression by dsm-iv, i.e., presence of delusions with a score higher than 2 (questionable delusion) rated by the scale for assessment of positive symptoms (saps; 51). 2. high suicide risk, i.e. intent or plan to attempt suicide in near future. 3. presence of any axis i psychiatric disorder or substance abuse other than unipolar major depression. 4. axis ii diagnosis of antisocial personality (by scid-p and dsm-iv). 5. history of psychiatric disorders other than unipolar major depression or generalized anxiety disorder (bipolar disorder, hypomania, are exclusion criteria). 6. cognition: mmse scores below 24 or diagnosis of dementia by dsm-iv. 7. acute or severe medical illness, i.e., delirium, metastatic cancer, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction during the three months prior to entry; or drugs known to cause depression, e.g., reserpine, alpha-methyl-dopa, steroids. 8. failure to respond to an adequate trial of escitalopram (10 mg/day or more for 6 weeks or longer) during the current or previous depressive episodes. 9. current involvement in psychotherapy. 10. history of hypersensitivity to escitalopram or need to receive drugs that may interact with escitalopram. 11. inability to perform any of the adls (mai: adl subscale) even with assistance, e.g. walking with a cane is not an exclusion criterion. 12. inability to speak english. 13. aphasia. 14. residence outside a 45-minute drive from cornell's clinical facilities. 15. patients taking maoi's and fluoxetine will be excluded.

Keywords: depression
quality of life among hungarian women with urinary incontinence

Conditions: Urinary Incontinence

Summary: the aim of this study is to assess the prevalence of urinary incontinence among hungarian women. in addition to that, we aim evaluate the health related quality of life among hungarian women with urinary incontinence and to culturally adapt the following questionnaires for the hungarian population: incontinence impact questionnaire - short form (iiq-7) and king's health questionnaire (khq).


Eligibility criteria:
inclusion criteria: * woman * age 18 and above * providing consent to participate * ability to read and write hungarian exclusion criteria: * respondents who are unable to complete the online survey due to illiteracy * man

Keywords: quality of life
combination chemotherapy in patients with advanced urinary tract cancer

Conditions: Bladder Cancer; Urethral Cancer

Summary: rationale: drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug and giving drugs in different ways may kill more tumor cells. purpose: this phase ii trial is studying how well combination chemotherapy works in treating patients with metastatic urinary tract cancer that cannot be treated with surgery.

objectives: * determine the efficacy of cisplatin, ifosfamide, and paclitaxel in patients with unresectable or metastatic urothelial cancer (nontransitional cell histologies). outline: patients receive paclitaxel iv over 3 hours and cisplatin iv over 1 hour on day 1 and ifosfamide iv over 1 hour on days 1-3. filgrastim (g-csf) is administered subcutaneously daily beginning on day 6 and continuing through day 17 or until blood counts recover. treatment continues every 3 weeks for a maximum of 6 courses in the absence of stable or progressive disease after completion of course 2 or complete response after completion of course 4. projected accrual: a total of 40 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * histologically proven unresectable or metastatic urothelial cancer * no transitional cell histologies * bidimensionally measurable disease patient characteristics: age: * 18 and over performance status: * karnofsky 60-100% hematopoietic: * wbc at least 3,500/mm\^3 * platelet count greater than 150,000/mm\^3 hepatic: * bilirubin less than 2.0 mg/dl renal: * creatinine less than 1.5 mg/dl or * creatinine clearance greater than 55 ml/min cardiovascular: * no new york heart association class iii or iv heart disease other: * no other concurrent malignancy except basal cell skin cancer prior concurrent therapy: biologic therapy * not specified chemotherapy * no prior systemic chemotherapy endocrine therapy * not specified radiotherapy * at least 3 weeks since prior radiotherapy surgery * not specified

Keywords: stage iii bladder cancer recurrent bladder cancer stage iv bladder cancer squamous cell carcinoma of the bladder adenocarcinoma of the bladder recurrent urethral cancer distal urethral cancer proximal urethral cancer urethral cancer associated with invasive bladder cancer
clinical study with an enteral formula with symbiotic and dha for malnourished children

Conditions: Cystic Fibrosis; Failure to Thrive; Malnutrition

Summary: the purpose of this study is to determine whether a nutritional supplement is effective in the treatment of malnutrition in pediatric patients with failure to thrive or cystic fibrosis.

this is a multicenter, controlled, randomized, prospective, parallel-group, double-blind study to evaluate the effect of a nutritional supplement on nutritional status in children with failure to thrive or cystic fibrosis. patients will be randomized to receive either a symbiotic formula with dha and antioxidants or a standard formula.

Eligibility criteria:
inclusion criteria: * malnutrition (p / t \<-1 sd) by intake deficit without organic disease (failure to thrive) and / or patients diagnosed with cystic fibrosis). * age \>= 1 year. * stable patients * no antibiotherapy in the last 30 days * inform consent signed (parent/legal representative) exclusion criteria: * patients with allergy / intolerance to cow's milk proteins * metabolically unstable patient * patients with metabolic intolerance to carbohydrates * patients with severe disease in the last 30 days

Keywords: malnutrition dietary supplement nutritional supplement symbiotic formula dha cystic fibrosis failure to thrive
an e-health psychoeducation for people with bipolar disorders

Conditions: Bipolar Disorder; Psychoeducation; COVID-19 Pandemic

Summary: this study aims to present data on the improvement of quality of life (qol), biological rhythms, anxiety, depressive symptoms and the correlations between qol and biorhythms following an e-health psychoeducational intervention for bipolar disoirder (bd) during covid-19 pandemic

biological rhythms significantly impact individuals' quality of life (qol). during the covid-19 pandemic, social rhythm dysregulation was identified as a contributing factor to relapses in bipolar disorder (bd). this trial aims to present data on the efficacy of an e-health psychoeducational intervention for bd in improving anxiety, depressive symptoms, qol, biological rhythms, and the correlations between qol and biorhythms. this study employs a cross-over randomized controlled trial design. inclusion criteria include a diagnosis of bd according to diagnostic and statistical manual of mental disorders (dsm-v) criteria, age over 18, and obtaining informed consent. the intervention consists of e-health psychoeducation aimed at reducing distress levels associated with the covid-19 pandemic and the implemented restrictive measures (lockdown). the focus is on strategies to manage the dysregulation of biological rhythms, with one session per week over two months. each session lasts approximately an hour and a half and is conducted by a team comprising psychologists, psychiatric rehabilitation technicians, and professional health educators.

Eligibility criteria:
inclusion criteria: * diagnosis of bd according to dsm-v, over 18 years old exclusion criteria: * do not have bipolar disorder, refusal to participate in the study

Keywords: bipolar disorder psychoeducation covid-19 pandemic
assessing the effectiveness of two treatment strategies for tension-type headache

Conditions: Tension-type Headache

Summary: the primary aim of the pilot data proposal is to compare usual care (medications) versus multi-disciplinary treatment in temporomandibular disorder (tmd) patients.

the primary aim of the pilot data proposal is to compare usual care (medications) versus multi-disciplinary treatment in tmd patients with episodic or chronic tension-type headache (tth) with pericranial tenderness involving the temporalis muscle at reducing the intensity of tth pain at 1 and 6 months. the hypothesis is that a team approach will reduce the intensity of headache more than usual care in this group of patients.

Eligibility criteria:
inclusion criteria: fifty consecutive subjects (age 18 to 65) will be included when they fulfill the diagnostic criteria for episodic or chronic tth with pericranial muscle tenderness3 and tmd including myofascial pain involving the temporalis muscle - exclusion criteria: exclusion criteria, assessed by review of medical history, include: * systemic rheumatic disease * widespread pain * pregnancy * concurrent use of tricyclic antidepressants, steroids, anti-inflammatories, muscle relaxants, or narcotics * major psychiatric disease * any medical contraindications

Keywords: headache elavil splints physical therapy behavioral therapy
race, natriuretic peptides and physiological perturbations

Conditions: Healthy; Pre Hypertension

Summary: the purpose of the study is to understand the origins of differential response to beta-blockers in african-americans and may provide insight regarding racial differences in cardiovascular risk.

the heart is an endocrine organ. the natriuretic peptides are hormones produced in the heart and are secreted in response to increased wall stress in atria and ventricles. the principal circulating nps are atrial natriuretic peptide (anp) and b-type natriuretic peptide (bnp). the endocrine actions of nps are natriuresis and dilatation of peripheral arteries. the nps concentrations are elevated in heart failure (hf) and hypertension (htn) due to volume and pressure overload. therefore, nps are used as diagnostic and prognostic markers in heart failure. however, nps role in healthy individuals is not known. previous studies have shown that reduced np levels are associated with a greater risk of htn. moreover, african-americans have lower resting np levels than caucasians. we hypothesize that relative np deficiency in african american compared to caucasian has the potential to contribute to increase risk of all-cause mortality, htn, hf and its sequelae. evidence from multiple clinical trials has positioned beta-blockers as a standard heart failure therapy. beta-blocker therapy leads to increased np levels and suppression of renin-aldosterone-angiotensin system (raas) system. suppression of renin levels by beta-blockers has been shown as a potential mechanism of benefit in hf. however, study shows that beta-blockers are less effective in african-americans compared to caucasians in hf treatment. so, the investigators have proposed a pilot study to look for race-based differences in the np and raas response to metoprolol in healthy individuals. additionally, exercise has been reported to increase np levels. anp increases more than bnp with exercise. but there is no data of np changes in african-american with exercise. so the investigators have proposed a sub-study of race-based difference in anp and bnp response to exercise. 40 african-american and 40 caucasians normotensive or pre-hypertensive (healthy) individuals will be enrolled.

Eligibility criteria:
inclusion criteria: * 18 to 40 years * blood pressure less than 140/90 mm hg * able to perform exercise capacity test * bmi 18-30 kg/m2 * willing to adhere to study drug exclusion criteria: * history of cardiovascular disease or use of medications for cvd * history of hypertension or use of bp lowering medications * blood pressure less than 100/60 mm hg * heart rate less than 60 beats/min * depression * diabetes or use of anti-diabetic medications * renal disease (egfr \< 60ml/min/1.73m2) * current or prior smokers * pregnant or use of hormone replacement therapy (hrt) or oral contraceptives (ocp) or steroids

Keywords: racial differences